Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT03773393

PHASE1

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Sponsor: Cellenkos, Inc.

View on ClinicalTrials.gov

Summary

The goal of this clinical research study is to determine whether it is safe and practical to give CK0801 (a Cord blood-derived T-regulatory cell product) to patients with bone marrow failure syndrome. Researchers want to determine the highest possible dose that is safe to be given. Researchers also want to learn if CK0801 may improve the symptoms of bone marrow failure syndrome. Patients enrolled in this study will all have been diagnosed with treatment refractory bone marrow failure syndrome (which includes aplastic anemia, myelodysplastic syndrome, or myelofibrosis). Participants eligible to participate in this study are unable or unwilling to be treated with standard therapy or have failed standard therapy.

Official title: Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2019-05-30

Completion Date

2027-05-30

Last Updated

2025-04-13

Healthy Volunteers

Conditions

Bone Marrow Disease

Interventions

BIOLOGICAL

CK0801

CK0801 (a Cord blood-derived T-regulatory cell product)

Inclusion Criteria: 1. Subjects who fulfill the diagnostic criteria of bone marrow failure syndrome including: aplastic anemia, myelodysplastic syndrome, or myelofibrosis. 2. HLA matched (≥ 3/6) cord blood unit available for CK0801 generation. 3. Subjects age ≥ 18 years. 4. Bilirubin ≤ 2 x ULN and SGPT (ALT) ≤ 2 x ULN (unless Gilbert's syndrome is documented). 5. Calculated creatinine clearance of \> 50mL/min using the Cockcroft-Gault equation. 6. Zubrod performance status ≤ 2. 7. Female subjects of child bearing potential (FPCP) must have a negative urine or serum pregnancy test. NOTE: FPCP is defined as premenopausal and not surgically sterilized. FPCP must agree to use maximally effective birth control or to abstain from heterosexual activity throughout the study. Effective contraceptive methods include intra-uterine device, oral and/or injectable hormonal; contraception, or 2 adequate barrier methods (e.g., cervical cap with spermicide, diaphragm with spermicide). 8. Subject has agreed to abide by all protocol required procedures including study-related assessments, visits and long term follow up. 9. Subject is willing and able to provide written informed consent. Exclusion Criteria: 1. Subject has received an investigational agent within 4 weeks prior to CK0801 infusion. 2. Subject has received radiation or chemotherapy within 21 days prior to CK0801 infusion. 3. Subject has received prior cord blood-derived T-regulatory therapy. 4. HIV seropositivity. 5. Subject has uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy. The Protocol PI is the final arbiter of eligibility. 6. Subjects with uncontrolled inter-current illness that in the opinion of the investigator would place the patient at greater risk of severe toxicity and/or impair the activity of CK0801 7. Subjects is pregnant or breastfeeding. 8. Bone marrow failure caused by stem cell transplantation. 9. Subjects who are unable to provide consent or who, in the opinion of the Investigator will be unlikely to fully comply with protocol requirements.

Locations (2)

Sarcoma Oncology Research Center, Cancer Center of Southern California

Santa Monica, California, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States